anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: Multiple myeloma is currently treated with a one-size-fits-all approach despite significant heterogeneity in patient outcomes and disease molecular constitution. A personalised approach would tailor therapy to unique patient or disease characteristics.
RECENT FINDINGS: Well established prognostic biomarkers such as cytogenetic risk and patient frailty status are being evaluated as potential predictive biomarkers. Specifically, treatment intensity can be augmented in high-risk patients or conversely attenuated in those at lower risk or lower ability to withstand treatment toxicities. Alternatively, targeted therapy can be rationally designed to exploit vulnerable pathways in myeloma cells as identified using predictive biomarkers. The t(11;14) translocation, found in approximately 15-20% of myeloma cases, is a leading biomarker for response to BCL-2 inhibitors such as venetoclax.
SUMMARY: Active research efforts exploring venetoclax combination therapies, as well as new generation BCL-2 inhibitors are underway. Following the development of venetoclax, numerous other cellular pathways are under investigation as candidate predictive biomarkers to rationally inform newer targeted therapies in myeloma.
Children with ASD and anxiety in our initial studies have displayed reductions in anxiety symptoms following the delivery of the FYF intervention. Given these initial successes, there are two primary purposes of this study. First, to train outpatient clinicians to fidelity on the FYF intervention for 8-14 year old children with high-functioning ASD and clinical anxiety. Second, to develop an optimal training model for learning the FYF intervention. The primary aims of Phase 1 are to develop a training manual and deliver a workshop on the FYF model to a group of outpatient clinicians in preparation for the clinicians to deliver the FYF intervention to four groups of children with ASD and anxiety. In Phase 2, the primary aims include comparing three instruction methods of learning to clinicians at three different outpatient clinics, by assessing increases in clinicians' acquisition of the intervention techniques and estimating the degree of reduction in anxiety symptoms on the primary outcome measures for the children with ASD. Instruction methods are: a) Manual, b) Workshop, c) Workshop-Plus. We hypothesize that clinicians receiving the Workshop-Plus (workshop plus ongoing consultation) condition will achieve treatment fidelity at a faster rate than clinicians receiving the other two instruction methods, and the children with ASD in the Workshop-Plus condition will display greater reductions in anxiety symptoms compared to the children in the other two conditions.
Lopinavir-ritonavir therapy was used in selected ICU patients before widespread availability of favipiravir (23 March 2020) and/or if favipiravir was contraindicated. Combination of lopinavir 200 mg-ritonavir 50 mg tablet was the given form. It was given as double tablets twice daily for 10-14 days. Patients were accepted as under favipiravir therapy if they had incomplete course of lopinavir-ritonavir therapy (less than 5 days) and followed by favipiravir for 5 days.
The present invention relates to a rotary medicine cabinet driven by an electric motor, and a smart medicine management system. A hollow rotary transparent medicine cabinet, which is assembled with concentric circles at the inside of a fixed circular cup-shaped hollow cylinder column, uses an electric motor that can be remotely controlled and a camera image to monitor a time of taking medicine, a method of recognizing the stored medicine, and whether or not the medicine is being taken to a user and a specific person. In addition, pills or plastic medicine bags safely stored in a storage space formed to fit the number of days of administration along the circumference inside the hollow rotary transparent medicine cabinet can be taken out by opening a ㄱ-shaped lid connected by male and female hinges on the side of a top plate. In addition, in a display window formed on the upper surface of the top plate, the record of taking time and medicine information, alarm, voice, video, clock, and battery information are provided by a menu mode button. At the same time, the information is shared by the user's and the specific person's smartphone and computer through the transmission/reception module and the mobile communication repeater. Rotation by an electric motor operated by remote control, blinking light connected to camera image data, alarm, and voice function inform the time of taking, how to take, and whether or not to take.
The aim of this paper is to review the history surrounding the discovery of lethal mutations, later described as delayed reproductive death. Lethal mutations were suggested very early on, to be due to a generalised instability in a cell population and are considered now to be one of the first demonstrations of "radiation-induced genomic instability" which led later to the establishment of the field of "non-targeted effects." The phenomenon was first described by Seymour et al. in 1986 and was confirmed by Trott's group in Europe and by Little and colleagues in the United States before being extended by Mendonca et al. in 1989, who showed conclusively that the distinguishing feature of lethal mutation occurrence was that it happened suddenly after about 9-10 population doublings in progeny which had survived the original dose of ionizing radiation. However, many authors then suggested that in fact, lethal mutations were implicit in the original experiments by Puck and Marcus in 1956 and were described in the extensive work by Sinclair in 1964, who followed clonal progeny for up to a year after irradiation and described "small colony formation" as a persistent consequence of ionizing radiation exposure. In this paper, we examine the history from 1956 to the present using the period from 1986-1989 as an anchor point to reach into the past and to go forward through the evolution of the field of low dose radiobiology where non-targeted effects predominate.
Device: No device. The functional kinematic training will be delivered as comparator treatment and will be carried out 3 days a week for 4 weeks.
The aim and objective of this single arm, prospective observational study is to describe patient reported outcomes (PRO) in severe eosinophilic asthma patients who are treated with benralizumab according to the label granted in Switzerland. The PRO measures consist of the weekly Asthma Control Questionnaire (ACQ-5) as well as Patient Global Impression of Change and Severity (PGI-C and PGI-S) collected at each visit (0, 1, 2, 4, 8, 16, 56 weeks). In addition the patient fills out twice daily the patient electronic asthma diary (eDiary) capturing daily symptoms and symptom free days together with a PEF (Peak Expiratory Flow) measurement. Persistance with eDiary and PEF will be assessed after 56 weeks. The percentage of patients successfully reducing their OCS dose will be evaluated after 16 weeks of treatment with benralizumab and if OCS reduction is persistent until week 56. Furthermore, the proportion of patients with an ACQ-5 score improvement of ≥ 0.5 after 8 weeks of treatment with benralizumab will be determined. In addition, the study will assess changes in FEV1 and FVC after 8, 16 and 56 weeks of treatment with benralizumab and describe retrospectively asthma disease history, past treatment status and current medication at baseline.
PURPOSE: To obtain a shampoo compsn. having more satisfactory conditioning characteristics. CONSTITUTION: A quat. imidazolinium compd. is added to a shampoo compsn. consisting of an anionic surfactant, a nonionic surfactant or a mixture of them, a suspending aid, nonvolatile silicone and water to obtain the objective shampoo compsn. having improved silicone depositing characteristics and conditioning characteristics. It is preferable that alkylene glycol monostearate or distearate is further added. About >0.1 g of this shampoo compsn. is applied to wetted hair and rinsed off.
Functional constipation is a common problem in childhood and has a great impact on social, physical, and emotional functioning of affected children and their caregivers. No organic cause of the constipation can be found in approximately 95% of children, defining the "so-called" chronic functional constipation. Its prevalence has been reported to range from 0.7 to 29.6%, with a median of 12%. The diagnosis of functional constipation is exclusively clinical based on the pediatric diagnostic Rome criteria for functional gastrointestinal disorders and does not routinely require laboratory and/or radiological investigations. In case of alarm signs and symptoms that may suggest organic diseases, further investigations can be required. The therapeutic management is based on non-pharmacological and pharmacological approaches. Education, demystification of constipation and reward-based toilet training represent the cornerstones of nonpharmacological management. Disimpaction, maintenance treatment and weaning of medication are all elements of pharmacological treatment. Osmotic laxatives, mainly polyethylene glycol (PEG), are considered the first-choice laxative for both disimpaction and maintenance treatment. The aim of this review is to provide pediatric gastroenterologists with a practical tool to support the clinical and therapeutic management of children and adolescents affected by chronic functional constipation.
The protocol consisted of first swabbing all points with alcohol, then pads of TENS were sticked on the proper location of acupoints included LI4, LI11, SP6 and ST36. Electrical output of one channel was administered to the surface of body via a combination of two pads. LI4 and LI11, ST36 and SP6 are combination of acupoints, respectively. Participants had 2 sessions per week, with total 5 weeks and 10 sessions. Each session lasted 30 minutes.
PURPOSE:To dispense with driving nails into a modesty panel by allowing a lower rear part which hangs to the rear side of the lower end of a decoration accessory to be engaged with a notched part of an underlayer exterior finish material by way of a water drip piece of a water drip joiner. CONSTITUTION:An underlayer exterior finish material 3 provided with a notched part 32 behind an upper end 31 is fixed with the surface of a wall underlayer material C where a front part 21, which hangs at the front of a lower end, is provided on the upper part of the underlayer exterior finish material 3, thereby fixing an upperlayer exterior finish material 2 whose thickness is smaller than the underlayer exterior finish material 3. There is formed a lower rear part 16, which hangs behind the lower end of an accessory main body 13 of a decorative accessory 1 which is lone sideways in the horizontal direction and fixed between the underlayer exterior finish material 3 and the upperlayer exterior finish material 2. The rear part 16 is engaged with the underlayer exterior finish material 3 by way of a water drip piece 41 of a water drip joiner 4. An upper rear part 11, which stands behind the upper end face of a decorative accessory 1, is engaged with the front part 21 of the upperlayer exterior finish material 2 by way of a water drip piece 51 of a water drip joiner 5. The top and the bottom of the decorative accessory are engaged respectively with the underlayer exterior finish material and the upperlayer exterior finish material, which makes it possible to fix the wall surface without driving nails.
Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
BACKGROUND: The number of dissected lymph nodes is closely related to the prognosis of patients with non-small cell lung cancer. This study explored the optimal number of right paratracheal lymph nodes dissected in right upper non-small cell lung cancer patients and its impact on prognosis.
METHODS: Patients who underwent radical surgery for right upper lobe cancer between 2012 and 2017 were retrospectively enrolled. The optimal number of right paratracheal lymph nodes and the relationship between the number of dissected right paratracheal lymph nodes and the prognosis of right upper non-small cell lung cancer were analysed.
RESULTS: A total of 241 patients were included. The optimal number of dissected right paratracheal lymph nodes was 6. The data were divided according to the number of dissected right paratracheal lymph nodes into groups RPLND + (≥ 6) and RPLND- (< 6). In the stage II and III patients, the 5-year overall survival rates were 39.0% and 48.2%, respectively (P = 0.033), and the 5-year recurrence-free survival rates were 32.8% and 41.8%, respectively (P = 0.043). Univariate and multivariate analyses revealed that among the stage II and III patients, ≥ 6 right paratracheal dissected lymph nodes was an independent prognostic factor for overall survival (HR = 0.53 95% CI 0.30-0.92 P = 0.025) and recurrence-free survival (HR = 1.94 95% CI 1.16-3.24 P = 0.011).
CONCLUSIONS: Resection of 6 or more right paratracheal lymph nodes may be associated with an improved prognosis in patients with right upper non-small cell lung cancer, especially in patients with stage II or III disease.
This group will receive routine physical therapy including strength training intervention. This protocol will be given for two weeks (6 sessions on alternate days, 3 sessions per week), outcomes will be measured at baseline, at the end of 1st week and 2nd week.
We developed an interpretable machine learning algorithm that prospectively predicts the risk of thrombocytopenia in older critically ill patients during their stay in the intensive care unit (ICU), ultimately aiding clinical decision-making and improving patient care. Data from 2286 geriatric patients who underwent surgery and were admitted to the ICU of Dongyang People's Hospital between 2012 and 2021 were retrospectively analyzed. Integrated algorithms were developed, and four machine-learning algorithms were used. Selected characteristics included common demographic data, biochemical indicators, and vital signs. Eight key variables were selected using the Least Absolute Shrinkage and Selection Operator and Random Forest Algorithm. Thrombocytopenia occurred in 18.2% of postoperative geriatric patients, with a higher mortality rate. The C5.0 model showed the best performance, with an area under the receiver operating characteristic curve close to 0.85, along with unparalleled accuracy, precision, specificity, recall, and balanced accuracy scores of 0.88, 0.98, 0.89, 0.98, and 0.85, respectively. The support vector machine model excelled at predictively assessing thrombocytopenia severity, demonstrating an accuracy rate of 0.80 in the MIMIC database. Thus, our machine learning-based models have considerable potential in effectively predicting the risk and severity of postoperative thrombocytopenia in geriatric ICU patients for better clinical decision-making and patient care.
Cerebral ischemia-reperfusion (I/R) injury is notably linked with folic acid (FA) deficiency. The aim of our investigation was to explore the effects and underlying mechanisms by which FA mitigates I/R, specifically through regulating the GCPII transcriptional adaptive program. Initially, we discovered that following cerebral I/R, levels of FA, methionine synthase (MTR), and methylenetetrahydrofolate reductase (MTHFR) were decreased, while GCPII expression was elevated. Secondly, administering FA could mitigate cognitive impairment and neuronal damage induced by I/R. Thirdly, the mechanism of FA supplementation involved suppressing the transcriptional factor Sp1, subsequently inhibiting GCPII transcription, reducing Glu content, obstructing cellular ferroptosis, and alleviating cerebral I/R injury. In summary, our data demonstrate that FA affords protection against cerebral I/R injury by inhibiting the GCPII transcriptional adaptive response. These findings unveil that targeting GCPII might be a viable therapeutic strategy for cerebral I/R.
In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
PURPOSE:To obtain a drug for burn by blending Euphorbia adenochlora Morr. et with pure sesame oil. CONSTITUTION:Euphorbia adenochlora Morr. et is blended with pure sesame oil and the blend is allowed to stand for about one year to provide the objective drug for burn. The above-mentioned drug is applied around the lesion and then sterilized gauze is applied thereon. The drug is free from side effects and the lesion is completely healed without leaving scar.
PURPOSE: To prepare an ocular composition for local administration, comprising an ocular decongestant and a labdane derivative and capable of suppressing the ocular hyperemia and lowering the intraocular pressure. CONSTITUTION: This ocular antihypertensive agent comprises an ocular decongestant such as phenylephrine and a labdane derivative of formula I [R1 is H, formula II (R2 is H, a lower alkyl, formula III, etc.), etc.; R6 and R7 are each H, formula IV, etc.; R9 is H or, together with R1 , forms formula IV, etc.] and is obtained by compounding a well-known suitable excipient therewith and formulating a pharmaceutical preparation according to a conventional method. The concentration of the phenylephrine in the ocular composition is 0.01-3.0wt.% and that of the labdane derivative is 0.1-1.0wt.%. The ocular composition is locally administered to eyes by using a tool such as an instillator and the dose thereof is 20μL administered at an interval of 2-3min three times. 7β-Deacetyl-7-β-(2,3-dihydroxypropionyl)forskolin is exemplified as the compound of formula I.
<P>PROBLEM TO BE SOLVED: To prepare a practical water-soluble type skin lotion and skin coating agent containing a tea polyphenol as a main agent, capable of suppressing discoloration by oxidation and withstanding long-term storage, and to obtain a bathing agent being readily produceable and conveniently useable and not polluting bathtubs.  <P>SOLUTION: An aqueous solution containing high-purity green tea polyphenol recently begun to be supplied for medical purpose and ascorbic acid is hermetically sealed in a PET (polyethylene telephthalate) bottle and stored. When the aqueous solution is used as the skin coating liquid, e.g. green tea polyphenol concentration is adjusted to 25 ppm and ascorbic acid concentration is adjusted to 2 ppm. When the aqueous solution is used as the bathing agent, the green tea polyphenol concentration is e.g. adjusted to about 1.0 wt.% and pH of the aqueous solution is kept to 3.0-5.0 by adding sodium ascorbate thereto and adjusting a ratio of sodium ascorbate to ascorbic acid.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Placebo Group (n=100). Subjects will receive placebo and will be instructed to take either 2 tabs per day for the first week then increase to 3 tabs per day for the remaining 6 months OR take 1 placebo tab for 6 months.
In order to improve the transfer of studies to a viewing application through a network, a cloud-based system is provided that optimizes the performance of imaging workflows. A client side application receives requests from an image viewing application. If the study is stored locally, the study including objects, are provided to the viewing application locally. Otherwise, the request is provided to the cloud-based system. The cloud-based system may include two processing components, an aggregator, and a retriever. The aggregator may collect the metadata about the study and may provide the metadata to the viewing application. The aggregator receives request for objects (e.g. images) from the viewing application and may priority the retrieval and processing of the requests based on information about the object such as its type, importance, and the metadata associated with the study.
Regardless of the indication, the starting dose in patients with moderate hepatic impairment should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerability. Patients with mild hepatic insufficiency do not require dosage reductions. The use of pilocarpine in patients with severe hepatic insufficiency is not recommended. If needed, refer to the Hepatic Insufficiency subsection of the Precautions section of this label for definitions of mild, moderate and severe hepatic impairment.

Head & Neck Cancer Patients: The recommended initial dose of Pilocarpine Hydrochloride Tablets is 5 mg taken three times a day. Dosage should be titrated according to therapeutic response and tolerance. The usual dosage range is up to 15-30 mg per day. (Not to exceed 10 mg per dose). Although early improvement may be realized, at least 12 weeks of uninterrupted therapy with Pilocarpine Hydrochloride Tablets may be necessary to assess whether a beneficial response will be achieved. The incidence of the most common adverse events increases with dose. The lowest dose that is tolerated and effective should be used for maintenance.

Sjogren's Syndrome Patients: The recommended dose of Pilocarpine Hydrochloride Tablets is 5 mg taken four times a day. Efficacy was established by 6 weeks of use.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy was usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of ibuprofen and famotidine tablet in patients with advanced renal disease. The renal effects of ibuprofen and famotidine tablet may hasten the progression of renal dysfunction in patients with pre-existing renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating ibuprofen and famotidine tablet. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of ibuprofen and famotidine tablet [see Drug Interactions (7)]. Avoid the use of ibuprofen and famotidine tablet in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal failure. If ibuprofen and famotidine tablet is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. 

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.